Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the closing of an $80 million Series B financing. The financing was led by Foresite Capital.
The WilmerHale team representing Fulcrum in this transaction included Lia Der Marderosian, Stephanie Singer and Andrea Sorrentino.
Fulcrum’s press release is available at www.fulcrumtx.com.
Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.
Thank you for your interest in WilmerHale.
